Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Short Report 2018

1 2 3

Press Releases

ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI

press release

October 24, 2016

Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a…

Read more

ObsEva Announces Plans to Conduct Initial Public Offering in the United States

press release

October 17, 2016

GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel…

Read more

ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

press release

October 12, 2016

– Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis…

Read more
1 78 79 80 81 82 86

General Meetings

ObsEva Annual General Meeting 2023

June 29, 2023

Read more

ObsEva Annual General Meeting 2022

May 18, 2022

Read more
1 2 3 4

Upcoming Events

Annual General Meeting: Thursday 27 June, 2024

Event


    Read more
     

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Investor relations


    IR@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    contact@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue